SCHEMBL15430987

SCHEMBL15430987

CC(C)c1cccn1C(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21916140 0.83 RIPK1 (0.31) RIPK1
SCHEMBL5859436 0.71 AOC3 (0.35) ALDH1A1MAPT
SCHEMBL16001291 0.69 ALDH1A1 (0.33) ALDH1A1MAPT
SCHEMBL732708 0.69
SCHEMBL21718636 0.67 ALDH1A1 (0.30) ALDH1A1MAPT
SCHEMBL21719937 0.67 ALDH1A1 (0.32) ALDH1A1MAPT
SCHEMBL98974 0.67
SCHEMBL20844220 0.67 ALDH1A1 (0.30) ALDH1A1MAPT
SCHEMBL840559 0.67 PTGS2 (0.34) RIPK1
SCHEMBL18438723 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584745-B2 Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2023-02-21 US disclosed
US-20210032241-A1 AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2021-02-04 US disclosed
US-20200101068-A1 Heteroaryl Derivatives as PARP Inhibitors LUPIN LIMITED (IN) 2020-04-02 US disclosed
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-04-11 US disclosed
US-20140024654-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032241-A1 AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF ALK, NOTUM, WEE1 RIPK1 2304/4885ALDH1A1 422/4885MAPT 3601/4885
US-20200101068-A1 Heteroaryl Derivatives as PARP Inhibitors PARP1, PARP2, PARP3 RIPK1 1935/4885ALDH1A1 1136/4885MAPT 756/4885
US-20140024654-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 RIPK1 837/4885ALDH1A1 337/4885MAPT 2563/4885
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF WEE1, WEE2, NME1 RIPK1 1212/4885ALDH1A1 2869/4885MAPT 4445/4885
US-11584745-B2 Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof ALK, NOTUM, WEE1 RIPK1 2304/4885ALDH1A1 422/4885MAPT 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.